Skip to content
OpenCapital
Get started

Ionis Pharmaceuticals IONS AFS and Trading Securities - Unrealized Loss Position (>=12 Months)

AFS and Trading Securities - Unrealized Loss Position (>=12 Months) at other companies

Exelixis logo
ExelixisEXEL
——

Other financials

Income statement

See full
Revenue$246.1M+87.0%
Gross profit$243.1M+86.8%
Operating income-$117.4M+20.0%
Net income-$92.5M+37.0%
EPS (diluted)-$0.56+39.8%

Balance sheet

See full
Cash & equivalents$173.4M-34.4%
Total debt$691.7M+334%
Total equity$491.4M+3.3%
Total assets$3.4B+22.6%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$21.8M+73.0%
Free cash flow-$814.6M-399%

Valuation

See full
Market cap$12.25B+159%
Enterprise value$12.77B+175%
P/S11.6×+5.0×

Profitability

See full
Gross margin98.4%-0.2pp
Operating margin-33.3%-11.0pp
Net margin-30.9%-10.5pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-67.6%-20.3pp
Debt / equity1.4×+1.1×
Current ratio4.1×-5.6×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger.

The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ionis Pharmaceuticals's afs and trading securities - unrealized loss position (>=12 months).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ionis Pharmaceuticals's AFS and trading securities - unrealized loss position (>=12 months)?
Ionis Pharmaceuticals (IONS) reported AFS and trading securities - unrealized loss position (>=12 months) of $11.32M in Q1 2026.
How has Ionis Pharmaceuticals's AFS and trading securities - unrealized loss position (>=12 months) changed year-over-year?
Ionis Pharmaceuticals's AFS and trading securities - unrealized loss position (>=12 months) decreased by 50.5% year-over-year, from $22.88M to $11.32M.